Genetic Determinants of Amyotrophic Lateral Sclerosis as Therapeutic Targets
Authors: A. Bosco, Daryl; E. Landers, John
Source: CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Volume 9, Number 6, December 2010 , pp. 779-790(12)
Publisher: Bentham Science Publishers
Abstract:Amyotrophic lateral sclerosis (ALS) is an incurable disease resulting from the deterioration of motor neurons. The onset of disease typically occurs in the fifth decade of life and progresses rapidly; death occurs for 75% of patients within 5 years. The only drug that is available to treat ALS is riluzole, which extends survival by just 2-3 months. Thus, new therapeutic directions are being sought to prolong the lifespan of ALS patients. Since the discovery of SOD1 as a genetic determinant of ALS in 1993, SOD1-models of ALS have been extensively employed for the development of ALS therapeutics. Novel genetic targets are now under investigation following the recent discoveries linking TDP-43, FUS/TLS, angiogenin, KIFAP3 and UNC13A to ALS. In this review, we present several of the genetic contributors to both sporadic and familial forms of ALS and discuss their potential as therapeutic targets for this devastating disease.
Keywords: (GWAS); ANGIOGENIN; Alzheimer's disease; Amyotrophic lateral sclerosis; DPP6; FALS; FUS/TLS; Huntington's disease; KIFAP3; Parkinson's disease; SALS; SOD1; TAR; TDP-43; UNC13A; angiogenin; arimoclomol; chaperones; familial ALS; frontotemporal lobar degeneration; genome-wide association; immunotherapy; neurodegeneration; therapy
Document Type: Research Article
Publication date: 2010-12-01
- CNS & Neurological Disorders - Drug Targets aims to cover all the latest and outstanding developments on the medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular targets involved in neurological and central nervous system (CNS) disorders e.g. disease specific proteins, receptors, enzymes, genes. Each issue of the journal will contain a series of timely in-depth reviews written by leaders in the field covering a range of current topics on drug targets involved in neurological and CNS disorders. As the discovery, identification, characterization and validation of novel human drug targets for neurological and CNS drug discovery continues to grow; this journal will be essential reading for all pharmaceutical scientists involved in drug discovery and development.